Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes
Type 1 diabetes is a proinflammatory state characterised by increased levels of circulating biomarkers of inflammation and monocyte activity. We have shown increased Toll-like receptor 2 (TLR2) and TLR4 expression and signalling in monocytes from type 1 diabetic patients. Several endogenous ligands of TLR2 and TLR4 have been identified; however, there is a paucity of data on levels of these endogenous ligands in diabetes. Thus, the aim of this study was to examine circulating levels of exogenous/endogenous ligands of TLR2 and TLR4 in type 1 diabetic patients and to compare these with the levels in matched healthy controls.
Healthy controls (n = 37) and type 1 diabetic patients (n = 34) were recruited, and a fasting blood sample was obtained. Circulating levels of endotoxin, heat-shock protein 60 (Hsp60), high-mobility group box 1 (HMGB1) and growth arrest-specific 6 (GAS6) proteins were assessed by ELISA, and TLR2 and TLR4 expression was determined by flow cytometry.
Levels of the classical TLR4 ligand, endotoxin, were significantly elevated in type 1 diabetic patients compared with those in matched controls. Hsp60 and HMGB1 concentrations were also significantly increased in the patients (p < 0.01 and p < 0.001, respectively). No significant differences were observed in GAS6.
We report the novel observation that levels of ligands of TLR2 and TLR4 are significantly elevated in type 1 diabetes, and this, in concert with hyperglycaemia, accounts for the increase in TLR2 and TLR4 activity, underscoring the proinflammatory state of type 1 diabetes.
- Libby P, Nathan DM, Abraham K et al (2005) Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111:3489–3493 CrossRef
- Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I (2006) Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 55:774–779 CrossRef
- Mullick AE, Tobias PS, Curtiss LK (2006) Toll-like receptors and atherosclerosis: key contributors in disease and health? Immunol Res 34:193–209 CrossRef
- Devaraj S, Dasu MR, Rockwood J et al (2008) Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 93:578–583 CrossRef
- Wagner H (2006) Endogenous TLR ligands and autoimmunity. Adv Immunol 91:159–173 CrossRef
- Osterloh A, Breloer M (2008) Heat shock proteins: linking danger and pathogen recognition. Med Microbiol Immunol 197:1–8 CrossRef
- Park JS, Gamboni-Robertson F, He Q et al (2006) High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 290:C917–C924 CrossRef
- Nagai K, Arai H, Yanagita M et al (2003) Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy. J Biol Chem 278:18229–18234 CrossRef
- Ghanim H, Mohanty P, Deopurkar R et al (2008) Acute modulation of toll-like receptors by insulin. Diabetes Care 31:1827–1831 CrossRef
- Creely SJ, McTernan PG, Kusminski CM et al (2007) Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 292:E740–E747 CrossRef
- Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 52, Issue 8 , pp 1665-1668
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Toll-like receptor
- Industry Sectors